There is no universal winner. Apollo Hospitals is the strongest choice for investors prioritising scale, diversification and a comparatively well-documented balance sheet. Rainbow Children’s Medicare offers the clearest specialist exposure to paediatrics, maternity and obstetrics/gynecology. Shalby is the smaller, orthopaedic-led growth thesis, but its concentration makes execution and valuation more important.
The better stock depends on the price you pay, the growth the market already expects, and whether you want a diversified hospital platform or a focused specialty operator. The operating figures below establish the business differences; a live valuation check is still essential before making any investment decision.
As an Amazon Associate I earn from qualifying purchases.
Quick answer: which hospital stock is better?
For a core hospital allocation, Apollo has the broadest verified operating base. Its FY2024–25 annual report records 8,025 operating beds, 10,187 total beds, 68% occupancy, consolidated revenue of ₹217,940 million and consolidated EBITDA of ₹30,219 million. It also reported 604 thousand discharges and 7.3 million outpatients, giving investors exposure to a large inpatient and outpatient ecosystem rather than one narrow clinical category.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Rainbow is the more differentiated specialist business. The National Stock Exchange describes its segment as “the business of running multi-specialty pediatric and obstetrics and gynecology hospital.” That focus can support brand strength, referral depth and higher-acuity case mix, but it also means investors should assess concentration in paediatric and women’s health services instead of treating Rainbow as a general hospital substitute.
#1 Best Overall
- [Ultra-Lightweight Ear Buds Designed for Small Ears] Each earbud weighs only 3.7g and features a compact, ergonomic in-ear design made especially for small ears. Secure, low-profile, and comfortable for workouts, all-day wear or overnight sleeping.The ultra-slim profile sits flush in your ear with no hard edges poking or rubbing, so you can even sleep on your side without discomfort.
- [Immersive Stereo Sound with TOZO OrigX Technology] TOZO OrigX tuning delivers clear vocals, balanced mids, and natural stereo sound for music, podcasts, and videos.
- [Long Battery Life for Daily Use] Get up to 7 hours of playtime on a single charge, with up to 32 hours total using the charging case—ideal for workdays, commuting, and extended listening sessions.
- [Bluetooth 5.3 & Stable Connection] Bluetooth 5.3 provides fast pairing, stable wireless performance, and reduced dropouts as you move around home or office.
- [Deep Bass with Clear Vocals] High-performance drivers produce punchy bass while keeping vocals clean and detailed for everyday listening.
Shalby is the smaller and more concentrated option, associated with an orthopaedic-led identity. A FY25 industry summary reported consolidated revenue of ₹1,086.96 crore, up 16.4% from ₹934 crore in FY24. That growth rate may appeal to investors looking for expansion from a smaller base, while the narrower platform creates more sensitivity to individual facilities, specialties and execution decisions.
These descriptions are business comparisons, not a buy signal. Hospital stocks can deliver very different returns from their operating performance when the entry multiple is high or when expansion requires substantial capital. Compare current price, market capitalisation and valuation multiples on the same date before ranking the three.
At-a-glance comparison
| Dimension | Apollo Hospitals | Rainbow Children’s Medicare | Shalby |
|---|---|---|---|
| Primary investment identity | Large, diversified hospital and healthcare platform | Focused paediatric, maternity and obstetrics/gynecology platform | Smaller, orthopaedic-led hospital platform |
| Verified FY25 revenue | ₹217,940 million consolidated revenue | ₹489.80 crore, up 14.2% year over year | ₹1,086.96 crore, up 16.4% from ₹934 crore in FY24 |
| Verified FY25 EBITDA | ₹30,219 million consolidated EBITDA | Not stated in the supplied company facts | Not stated in the supplied company facts |
| Verified capacity | 8,025 operating beds; 10,187 total beds | Current capacity not stated in the supplied company facts | Current capacity not stated in the supplied company facts |
| Verified occupancy | 68% | Not stated in the supplied company facts | Not stated in the supplied company facts |
| Specialty exposure | Broad hospital and healthcare exposure | Paediatrics, maternity, obstetrics and gynecology | Orthopaedic-led, with other hospital services |
| Balance-sheet reference | FY25 debt-equity ratio of 0.26 | Not stated in the supplied company facts | Not stated in the supplied company facts |
| Best suited to | Investors seeking scale and diversification | Investors seeking a focused specialty healthcare thesis | Investors accepting concentration for smaller-base growth potential |
The table deliberately separates verified figures from data that was not stated. Do not infer current bed counts, margins or leverage for Rainbow or Shalby from older market commentary.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Company-by-company analysis
Apollo Hospitals: the scale and diversification leader
Apollo’s FY2024–25 numbers make it the largest and most diversified operating platform among the three on the verified evidence. The annual report records 8,025 operating beds and 10,187 total beds, with occupancy of 68%. The distinction matters: operating beds represent the beds available for active operations, while total beds can include capacity not yet operating in the same way. Investors should therefore use the correct denominator when comparing occupancy or calculating revenue per bed.
Consolidated revenue was ₹217,940 million and consolidated EBITDA was ₹30,219 million. The revenue base spans a much larger network than the other two companies’ figures reported here. Apollo also reported 604 thousand discharges and 7.3 million outpatients, indicating that its economics are not dependent only on occupied inpatient beds. Outpatient visits can feed diagnostics, pharmacy, procedures and later admissions, although the contribution of each activity must be checked in the latest segment disclosures.
A FY25 debt-equity ratio of 0.26 provides a useful balance-sheet reference point. It does not eliminate financial risk: hospital expansion, acquisitions, equipment purchases and lease commitments can still affect cash flow and leverage. It does, however, give investors a concrete starting point for comparing funding intensity with smaller peers once their latest debt, lease liabilities and cash balances are collected.
Apollo’s main analytical challenge is not simply whether it can grow, but whether the large base can continue compounding at an attractive return on capital. Mature networks may have more predictable demand and purchasing advantages, yet they can also face slower percentage growth, heavier fixed costs and more complex capital-allocation choices.
Rank #2
- 【IP68 Waterproof Multifunctinal Smart Watch】Torjalph fitness activity tracker smart watch is IP68 waterproof technology ,you can wear it when swimming,handwashing,it's rain-proof which means that you perform multiple exercise modes outside without worrying about sweat or rain corroding your fitness smart watch,and this watch equipped with a 230 mAh large capacity battery magnetic charging ,and this sports activity tracker watch can be used 5-7 days If fully charged.
- 【Larger 1.83'' Full Screen Watch & Multi-dial Selection】1.83 inch full HD color touch screen smart watch for men / women provides excellent 240*284 resolution image quality ,This Bluetooth smart watch offers a better touch experience and remarkable immersion and ,more than 200 watch faces for you to choose from App"Da Fit ", you can change the dial style according to your mood to wear keeping the world on your wrist
- 【Accurate Activity Tracker Smart Watch 】sports watch activity tracker uses sweat and dust resistant breathable silicone strap, our Fitness Tracker Smart Watch for Android iOS Phones supports 12 sports modes,walking,running,bicycle,swimming,badminton,basketball,football,rope skipping. This bluetooth calls smart watch for men women is lightweight and stylish, bringing more convenient and relaxing sports experience while also providing more protection.
- 【Your 24 Hour Personal Daily Health Monitor】Fitness watch for women men full touch screen IP67 waterproof bluetooth smartwatch for Android iOS Phones with heart rate blood pressure monitor multifunction Andriod smart watch with steps counter sleep monitor sports fitness watch, monitoring blood oxygen saturation allows you to understand your physical condition in real time to track fitness progress ,to know your health status in time.
- 【More Functions Bluetooth Call Smart Watch】This fitness activity smart watch full screen for iPhone and Android phones includes a bunch of new features including:The bluetooth smart watch can hang up the phone, receive and display WhatsAPP /Text /Facebook /Twitter /Messenger reminder.Support sedentary reminder, alarm clock, stopwatch, timer,weather information,music control, remote camera control compatible with Android 5.0 and above or iOS 9.0 and above smartphones.
Rainbow Children’s Medicare: focused paediatric and women’s health exposure
Rainbow’s defining characteristic is specialty concentration. The NSE filing describes its business as “the business of running multi-specialty pediatric and obstetrics and gynecology hospital.” That wording points to a deliberate clinical focus rather than a generalist network assembled across every major specialty.
A focused platform can create several advantages. Clinicians may build deeper referral relationships in paediatrics and women’s health; operating teams can standardise protocols across similar hospitals; and a recognised specialty brand may support occupancy and pricing in catchment areas where families value high-acuity paediatric care. These are hypotheses to test against occupancy, case mix, payer mix, doctor retention and new-hospital ramp-up data, not automatic outcomes.
Rainbow’s FY25 revenue was reported at ₹489.80 crore, up 14.2% year over year, according to a 2025 Medical Buyer summary. Revenue growth should be read alongside the number of mature hospitals, newly opened facilities and any contribution from acquisitions. A percentage increase driven by recently added capacity has different implications from same-hospital growth generated by higher occupancy or better realisations.
The specialist model also carries concentration risks. Changes in birth rates, local competition, reimbursement arrangements, clinician availability or referral patterns can have an outsized effect on a paediatric and maternity-focused chain. Investors should examine how much revenue comes from the largest hospitals and whether the company is broadening services without losing its specialty identity.
Shalby: a smaller-base, orthopaedic-led thesis
Shalby is the most concentrated of the three in the comparison and is identified with orthopaedic care. Its FY25 consolidated revenue was reported at ₹1,086.96 crore, compared with ₹934 crore in FY24, a 16.4% increase. The absolute base is much smaller than Apollo’s, so a few new facilities, service lines or capacity additions can move the reported growth rate materially.
Orthopaedics can be an attractive hospital niche because procedures such as joint replacement require specialised teams, implants, rehabilitation and follow-up care. They can also expose the operator to implant costs, surgeon dependence, insurance authorisation and elective-procedure cycles. The relevant question is not whether orthopaedics is attractive in general, but whether Shalby converts its clinical reputation into sustained occupancy, pricing, operating margins and cash generation.
Small-company growth deserves a higher level of operational scrutiny. Review hospital-level occupancy, average revenue per occupied bed, length of stay, case mix, doctor productivity, new-unit ramp-up and maintenance capital expenditure. Concentration in a smaller number of hospitals means a temporary closure, regulatory issue, key-doctor departure or local competitor can affect consolidated results more than it would at a large diversified network.
Rank #3
- [Low Noise High Fidelity] New bee guitar cord with 22AWG oxygen-free-copper center conductors provides enhanced signal transfer, the PVC insulation material and the high-density stranded copper double shield provide noise rejection for quiet operation
- [Ideal for Choice] New bee 1/4 straight and right angle metal connectors, ensures a secure connection in any instrument, pedal, or amp jack. L shape great fro on stage guitar stands
- [Wide Compatible] Suitable for mixer, power amplifier, microphone, effector, decoder, equalizer, electoronic organ, electric guitar, electric bass and other electronic equipments. Widely used in the installation of smart home, karaoke speaker, professional stage audio, etc
- [Easy Disassemble] Making incidental repairs quick and easy! Very nice, flexible cable
- [Dont Hesite to Order] 24 hours customer services and professional technology team are standing by
Shalby’s 16.4% FY25 revenue growth is therefore a useful starting signal, not a forecast. Determine how much came from existing hospitals, new beds, acquisitions, price changes and non-hospital activities before assigning a long-term growth rate.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Historical capacity context: useful, but not current
An Axis Capital Rainbow IPO note reported FY2021 figures of 14 hospitals and 1,475 beds for Rainbow, versus 11 hospitals and 2,012 beds for Shalby. It also reported FY2021 average revenue per occupied bed (ARPOB) of ₹40.9 thousand for Rainbow and ₹27.4 thousand for Shalby.
These numbers are useful for understanding the companies’ historical positioning: Rainbow had fewer beds but higher reported ARPOB, while Shalby had more beds in that period. They must not be presented as current capacity or current pricing. Hospital networks change through additions, closures, relocations, acquisitions and changes in reporting definitions. Use the latest annual reports and exchange filings when calculating today’s bed count or ARPOB.
What to compare beyond revenue
Occupancy and bed additions
Occupancy shows how much installed capacity is being used, but it should be paired with the number of operating beds. A chain can grow revenue by adding beds while occupancy temporarily falls during the ramp-up period. Conversely, high occupancy can signal strong demand but also limited room to grow without new capacity.
- Track operating beds, total beds and additions separately.
- Measure occupancy by hospital and for the consolidated network.
- Identify how many beds are mature, recently opened or temporarily unavailable.
- Check whether expansion is funded from operating cash flow, debt, equity or leases.
ARPOB, case mix and payer mix
ARPOB is average revenue per occupied bed, not a complete measure of profitability. It can rise because of more complex procedures, higher prices, a different specialty mix or a greater share of private-pay patients. Compare ARPOB with length of stay, occupancy and EBITDA margin so that higher revenue is not mistaken for higher economic value.
Free tools Windows power users keep installed
One-click scans. No signup required.
Case mix matters particularly in this comparison. Rainbow’s paediatric and obstetrics/gynecology focus, Shalby’s orthopaedic identity and Apollo’s broader platform can produce very different revenue and cost profiles. Ask whether reported growth reflects more high-acuity cases, more surgeries, outpatient expansion or simply additional beds.
EBITDA margin and cash conversion
EBITDA indicates operating earnings before interest, tax, depreciation and amortisation, but hospitals require continuing investment in buildings, medical equipment, technology and working capital. Compare EBITDA margin with operating cash flow and capital expenditure. A business can report attractive EBITDA while consuming cash during an aggressive expansion phase.
Rank #4
- Digital Family Calendar: BSIMB digital calendar wall touch screen puts an end to your chaotic life. Designed for busy families, the digital calendar keeps you organised and in step with your family. Assign different colours and tasks to each family member to make family scheduling easier and more intuitive.
- Easy Setup and Auto-Sync: Plug in, connect to WLAN and auto-syn your electric calendar in minutes. Digital wall calendar compatible with Google calendar, iCloud calendar, Outlook calendar, Cozi calendar and Yahoo calendar. Add events directly on the device or through the ecalendar app. Electronic calendar stays current whether you're at work or traveling—no manual updates needed.
- All-In-One Home Assistant: Smart calendar builds habits and encourage independence with personalised chores. Display daily meal plan to reduce the daily ‘What's for dinner?’ stress. To-do lists keep track of everything you want. Turning chores into valuable achievements with stars and rewards, making life easier and more enjoyable.
- Manage Anytime Anywhere: BSIMB electronic calendar for family stay connected with the powerful ecalendar app. Access and manage your digital wall calendar anytime, anywhere with free features like stars & rewards, photo screensaver, chore charts, meals plans, to-do lists etc. Electronic planner paid features like Magic Import tailor advanced tools for users with special needs.
- Stay in Touch with Loved Ones: Share photos or videos from your phone to electronic wall calendar with app, instantly update your life moment, and keep in touch with your family, especially those who are far away; you can also surprise your smart calendar digital wall by sending him a wish card; it's also great for keeping tech-illiterate elders in touch with the youngsters.
For Apollo, the FY25 revenue and EBITDA figures imply a consolidated EBITDA margin of approximately 13.9% when ₹30,219 million is divided by ₹217,940 million. This is a calculation from the reported figures, not a margin stated separately in the annual-report facts above. Obtain comparable, consistently defined EBITDA figures for Rainbow and Shalby before ranking margins.
Leverage and fixed obligations
Apollo’s FY25 debt-equity ratio of 0.26 is the only directly verified leverage figure in the comparison. For all three companies, inspect borrowings, lease liabilities, interest expense, maturity schedules, pledged shares and contingent liabilities. Debt-equity alone may understate obligations when leases are material or when expansion is housed in subsidiaries.
Recommended Free Tools
Doctor and referral dependence
Hospitals are people-intensive businesses. Examine consultant retention, employment versus visiting-doctor models, revenue concentration among leading clinicians and the depth of referral networks. A specialty operator can benefit from clinical expertise but may also be more exposed to the departure of a small number of doctors.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Valuation snapshot to refresh on the publication date
Share prices and valuation multiples change continuously. The supplied company facts do not provide a synchronized NSE/BSE price, market capitalisation, enterprise value, EV/EBITDA or P/E for all three companies. The following table is therefore a publication-day checklist rather than a fabricated quote. Fill every row from exchange data and the latest comparable financial period before using valuation to make a decision.
| As at 18 October 2026 | Shalby | Apollo Hospitals | Rainbow Children’s Medicare |
|---|---|---|---|
| NSE/BSE share price | Not stated; refresh from exchange data on publication day | Not stated; refresh from exchange data on publication day | Not stated; refresh from exchange data on publication day |
| Market capitalisation | Not stated; calculate using the same date and share-count basis | Not stated; calculate using the same date and share-count basis | Not stated; calculate using the same date and share-count basis |
| Enterprise value | Not stated; reconcile debt, cash and lease treatment | Not stated; reconcile debt, cash and lease treatment | Not stated; reconcile debt, cash and lease treatment |
| EV/EBITDA | Not stated; use a consistent trailing or forward period | Not stated; use a consistent trailing or forward period | Not stated; use a consistent trailing or forward period |
| P/E | Not stated; use the same earnings period for all three | Not stated; use the same earnings period for all three | Not stated; use the same earnings period for all three |
Do not compare one company’s trailing P/E with another company’s forward P/E. State whether earnings are consolidated, whether exceptional items are included, and whether the denominator uses reported profit or an adjusted figure. For EV/EBITDA, disclose how leases and minority interests are treated.
How valuation changes the answer
When Apollo can justify a premium
Apollo may deserve a higher multiple if its scale produces durable occupancy, stronger purchasing economics, broad referral flows, resilient cash generation and disciplined capital allocation. A premium becomes harder to justify if growth depends on increasingly expensive acquisitions, if mature hospitals stagnate or if returns on new capacity decline.
When Rainbow can justify a premium
Rainbow’s premium case rests on specialty leadership, sustainable same-hospital growth, high-quality clinical outcomes, efficient new-hospital ramps and attractive returns on expansion. The market may already price in years of specialty growth, so verify the implied growth rate rather than assuming a strong niche automatically means an undervalued stock.
When Shalby can justify a premium
Shalby could merit a higher valuation if its orthopaedic franchise supports repeatable pricing, strong utilisation, high cash conversion and successful expansion beyond its existing base. The discount case is equally important: concentration, lower scale, dependence on key clinicians or debt-funded growth can warrant a lower multiple even when reported revenue growth is faster.
Use an earnings-yield and growth sanity check
Translate each stock’s valuation into the growth and margin assumptions required to earn an acceptable return. Ask what happens if revenue growth slows by five percentage points, occupancy takes two years longer to mature, or EBITDA margin falls during expansion. A sensitivity table is more useful than a single target price because hospital outcomes depend on several operating variables at once.
A practical decision framework
- Choose the exposure you actually want. Select broad healthcare diversification, paediatric and women’s health specialisation, or an orthopaedic-led smaller platform before looking at the ticker.
- Standardise the financial period. Use the latest annual or quarterly figures available for all three, and label trailing versus forward numbers.
- Build a hospital-level operating view. Record operating beds, occupancy, ARPOB, case mix, payer mix, new-bed additions and maturity of each facility.
- Test cash economics. Compare EBITDA with operating cash flow, maintenance capital expenditure, expansion capital expenditure and working-capital movements.
- Stress the balance sheet. Include debt, leases, interest costs, contingent liabilities and the funding required for announced projects.
- Refresh valuation on one date. Use the same price timestamp, share-count convention, debt definition and earnings denominator.
- Set a position size based on uncertainty. A concentrated specialty or small-cap thesis generally deserves a smaller position than a diversified core holding unless your evidence and risk tolerance support otherwise.
Risks that can invalidate the thesis
- Regulatory and reimbursement changes: price controls, insurance rules, accreditation requirements or changes in public-program payments can affect realisations and margins.
- Execution risk: new hospitals may take longer to reach sustainable occupancy, while construction delays can increase project costs.
- Clinical and reputational risk: adverse events, infection-control failures or compliance issues can reduce referrals and increase liabilities.
- Talent risk: losing prominent surgeons, paediatricians, obstetricians or hospital administrators can weaken a facility’s referral engine.
- Input-cost inflation: implants, medicines, wages, utilities and outsourced services can rise faster than patient pricing.
- Capital-allocation risk: acquisitions or rapid expansion can destroy value if returns remain below the cost of capital.
- Concentration risk: Rainbow’s specialty focus and Shalby’s smaller orthopaedic-led platform can make local disruptions more material than at a diversified network.
- Valuation compression: even good operating results may produce poor share returns if the starting multiple falls.
Which investor profile fits each stock?
Choose Apollo for scale and diversification
Apollo is the logical starting point for an investor who wants a broad hospital platform, substantial operating capacity and a clearer FY25 disclosure base. The trade-off is that a larger company may offer less percentage growth than a successful smaller operator, and a premium valuation can remove much of the benefit of operational quality.
Choose Rainbow for specialist healthcare exposure
Rainbow fits an investor who understands paediatric and women’s health demand drivers and is comfortable analysing specialty concentration. Confirm that occupancy, ARPOB, margins and new-unit returns support the premium the market assigns to the focused model.
Choose Shalby for a smaller-base growth thesis
Shalby fits an investor willing to do more hospital-level work and tolerate greater concentration. Its FY25 revenue growth is encouraging, but the investment case depends on the durability and cash quality of that growth, not on one year’s percentage increase.
Bottom line
On verified operating scale, Apollo leads. On focused specialty exposure, Rainbow is the clearest choice. On smaller-base, orthopaedic-led growth, Shalby offers the most concentrated thesis. None is automatically the best investment: the final ranking must combine occupancy, ARPOB, case mix, EBITDA margin, cash conversion, leverage and a dated valuation comparison. Refresh the NSE/BSE prices and multiples immediately before investing, then choose the business whose expected return still compensates you for its specific risks.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
